farglitazar profile

farglitazar: a non-thiazolidinedione insulin sensitiser and PPARgamma agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	170364
CHEMBL ID	107367
SCHEMBL ID	501024
MeSH ID	M0382005

Synonym
(2s)-2-[[2-(benzoyl)phenyl]amino]-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
gtpl2672
2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid
D04132
farglitazar (usan/inn)
CMAP_000025
l-tyrosine, n-(2-benzoylphenyl)-o-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-
gi-262570
l-tyrosine, n-(2-benzoylphenyl)-o-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9ci)
gi 262570x
farglitazar
gi 262570
196808-45-4
1FM9
gi262570
farglitazar [usan]
l-tyrosine, n-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-
n-(o-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-l-tyrosine
l-tyrosine, n-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)
KBIO2_004915
KBIOGR_002347
KBIO2_002347
KBIOSS_002350
KBIO2_007483
gi-2570
gi2570
gi 2570
bdbm50085044
(s)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid
(s)-2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid
2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid(gi 262570)
g1-262570
gi262570x
gi-262570x
CHEMBL107367 ,
(2s)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
NCGC00247940-01
dtxsid1047310 ,
cas-196808-45-4
dtxcid9027310
tox21_300218
NCGC00254050-01
farglitazar [usan:inn]
3433gy7132 ,
unii-3433gy7132
farglitazar [who-dd]
farglitazar [inn]
274687-78-4
ZZCHHVUQYRMYLW-HKBQPEDESA-N
SCHEMBL501024
AKOS027326860
gi262570; farglitazar
o-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-n-[2-(phenylcarbonyl)phenyl]-l-tyrosine
Q5435087
(s)-2-((2-benzoylphenyl)amino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid
g1 262570; gi 262570; gi 262570x
(s)-2-((2-benzoylphenyl)amino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoicacid
HY-105074
CS-0024894

Excerpt	Relevance	Reference
" Finally, 63 was found to normalize glycemia when dosed at 3 mg/kg bid po in the Zucker diabetic fatty rat model of type 2 diabetes."	( N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ, 1998)	0.3
" In a well-characterized cell culture model of the principal cell type [Madin-Darby canine kidney (MDCK)-C7], PPARgamma agonists inhibit vasopressin-stimulated Cl(-) secretion with agonist dose-response relationships that mirror receptor transactivation profiles."	( PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Ashton, TT; Baines, D; Bisi, J; Blazer-Yost, BL; Brown, KK; Harrington, W; Kalsi, K; Maurio, FP; Murray, D; Nofziger, C; Smith, CD; West, TA, 2009)	0.35
" This work evaluated and compared the response of N-terminal proatrial natriuretic peptide (NT-proANP) and N-terminal probrain natriuretic peptide (NT-proBNP) in rats during exercise-induced and drug-induced increases in cardiac mass after chronic swimming or daily oral dosing with a peroxisome proliferator-activated receptor γ agonist."	( Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular Hypertrophy. Agostinucci, K; Colton, HM; Dunn, ME; Engle, SK; Gallacher, M; Gropp, KE; King, NM; Manfredi, TG; More, V; Powe, J; Rodriguez, LA; Serra, D; Shimpi, P; Vetter, FJ, 2017)	0.46

Protein Targets (46)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	89.3584	0.0072	15.7588	89.3584	AID1224835
acetylcholinesterase	Homo sapiens (human)	Potency	56.3813	0.0025	41.7960	15,848.9004	AID1347397
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	51.9536	3.1890	29.8841	59.4836	AID1224846; AID1224894
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	61.1306	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	21.8724	0.1737	34.3047	61.8120	AID1346859
SMAD family member 3	Homo sapiens (human)	Potency	21.8724	0.1737	34.3047	61.8120	AID1346859
GLI family zinc finger 3	Homo sapiens (human)	Potency	34.6044	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	31.5765	0.0002	21.2231	8,912.5098	AID743035; AID743036; AID743042; AID743053; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	68.5896	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	27.3060	0.0006	57.9133	22,387.1992	AID1259378
progesterone receptor	Homo sapiens (human)	Potency	68.5896	0.0004	17.9460	75.1148	AID1346795
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	51.8270	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	32.3936	0.0030	41.6115	22,387.1992	AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	9.0549	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	66.3635	0.0015	30.6073	15,848.9004	AID1224841; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	20.6831	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	76.9588	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	43.6493	0.0002	29.3054	16,493.5996	AID1259248; AID743069; AID743078; AID743079
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	17.8383	0.0010	24.5048	61.6448	AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	22.8542	0.0010	19.4141	70.9645	AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	12.8362	0.0237	23.2282	63.5986	AID743222; AID743223; AID743241
caspase-3	Homo sapiens (human)	Potency	68.5896	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	68.5896	0.0017	23.8393	78.1014	AID743083
activating transcription factor 6	Homo sapiens (human)	Potency	61.6448	0.1434	27.6121	59.8106	AID1159516; AID1159519
thyrotropin-releasing hormone receptor	Homo sapiens (human)	Potency	30.1475	0.1549	17.8702	43.6557	AID1346877
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	54.9410	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	54.9410	0.0578	21.1097	61.2679	AID1159526
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	44.9878	0.0391	47.5451	146.8240	AID1224845
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	30.6379	0.0067	23.4960	68.5896	AID1346980
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	30.6379	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	36.6523	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	47.7544	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	18.3755	0.0006	27.2152	1,122.0200	AID743202; AID743219
Cellular tumor antigen p53	Homo sapiens (human)	Potency	31.9792	0.0023	19.5956	74.0614	AID651631; AID720552
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	68.5896	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	68.5896	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain D, PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA	Homo sapiens (human)	Ki	0.0010	0.0010	0.0010	0.0010	AID977610
Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)	IC50 (µMol)	0.1210	0.0050	1.2051	10.0000	AID276984; AID306520
Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)	Ki	22,388.8009	0.0000	0.3790	5.6000	AID157099; AID157270; AID157271; AID157275; AID599141
Peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Ki	1.2000	0.0000	0.5141	3.1623	AID156776
Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)	IC50 (µMol)	2.0435	0.0005	0.8269	6.3100	AID276983; AID306524
Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)	Ki	0.4899	0.0001	1.0189	4.5000	AID156288; AID156444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0003	0.0000	1.2626	10.0000	AID141913
Muscarinic acetylcholine receptor M3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0003	0.0000	0.7646	10.0000	AID141913
Muscarinic acetylcholine receptor M4	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0003	0.0000	0.9905	10.0000	AID141913
Muscarinic acetylcholine receptor M5	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0003	0.0000	1.0528	10.0000	AID141913
Muscarinic acetylcholine receptor M2	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0003	0.0000	1.1605	10.0000	AID141913
Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)	EC50 (µMol)	0.0020	0.0000	0.9922	10.0000	AID1507887; AID156931; AID157119; AID157120; AID157121; AID157123; AID157124; AID157126; AID276984; AID306521; AID484773; AID643835; AID643837; AID643839; AID643841; AID91246
Peroxisome proliferator-activated receptor gamma	Mus musculus (house mouse)	EC50 (µMol)	0.0004	0.0003	1.6542	10.0000	AID141913; AID157281
Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)	EC50 (µMol)	0.3717	0.0006	1.6074	10.0000	AID1507885; AID156130; AID156440; AID156442; AID276983; AID306525; AID91237
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Log Ki	6.0700	6.0700	6.1100	6.1500	AID156783
Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)	Log Ki	6.3100	5.5000	5.9050	6.3100	AID156448
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (266)

Process	via Protein(s)	Taxonomy
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of cholesterol efflux	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
long-chain fatty acid transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of osteoblast differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of receptor signaling pathway via STAT	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of low-density lipoprotein receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of signaling receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of MAP kinase activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adiponectin secretion	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stress	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healing	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
placenta development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to nutrient	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of blood pressure	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cholesterol storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of lipid storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of sequestering of triglyceride	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of angiogenesis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
monocyte differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
epithelial cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to lipid	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peroxisome proliferator activated receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
glucose homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of circadian rhythm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipoprotein transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
innate immune response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell fate commitment	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
retinoic acid receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell maturation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
rhythmic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
white fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of SMAD protein signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cholesterol transporter activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to hypoxia	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of mitochondrial fission	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of extracellular matrix assembly	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adipose tissue development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular endothelial cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of inflammatory response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
hormone-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
glucose metabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
generation of precursor metabolites and energy	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
lipid metabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
fatty acid beta-oxidation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
apoptotic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
embryo implantation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cholesterol metabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cell population proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
axon ensheathment	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
fatty acid catabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
regulation of skeletal muscle satellite cell proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
fatty acid transport	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
intracellular receptor signaling pathway	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cell-substrate adhesion	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cellular response to nutrient levels	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
wound healing	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
steroid hormone mediated signaling pathway	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of skeletal muscle tissue regeneration	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
keratinocyte proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of fat cell differentiation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of myoblast differentiation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
decidualization	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
keratinocyte migration	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
adipose tissue development	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
fat cell proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of fat cell proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cellular response to hypoxia	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
energy homeostasis	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
apoptotic signaling pathway	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
glucose transmembrane transport	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of myoblast proliferation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
fatty acid metabolic process	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of cholesterol storage	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
cell differentiation	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of inflammatory response	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
hormone-mediated signaling pathway	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of reactive oxygen species biosynthetic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of hepatocyte apoptotic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of signaling receptor activity	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of ATP biosynthetic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of transformation of host cell by virus	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
response to hypoxia	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
gluconeogenesis	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
heart development	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
response to nutrient	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
epidermis development	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
cellular response to starvation	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
regulation of cellular ketone metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of cholesterol storage	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of sequestering of triglyceride	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
intracellular receptor signaling pathway	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of fatty acid beta-oxidation	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of appetite	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
response to insulin	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
circadian regulation of gene expression	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
behavioral response to nicotine	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
wound healing	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
lipoprotein metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
regulation of circadian rhythm	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
steroid hormone mediated signaling pathway	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
response to ethanol	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of gluconeogenesis	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of blood pressure	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of glycolytic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
nitric oxide metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of fatty acid oxidation	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of lipid biosynthetic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of inflammatory response	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell development	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
enamel mineralization	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
cellular response to fructose stimulus	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
negative regulation of leukocyte cell-cell adhesion	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
regulation of fatty acid transport	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
hormone-mediated signaling pathway	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
fatty acid metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
positive regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
cell differentiation	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
transcription cis-regulatory region binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
transcription coregulator binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
double-stranded DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
prostaglandin receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
zinc ion binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
enzyme binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peptide binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
identical protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear retinoid X receptor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
arachidonic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
LBD domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
alpha-actinin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
R-SMAD binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
E-box binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
STAT family protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
transcription coactivator binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
DNA binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
nuclear steroid receptor activity	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
nuclear receptor activity	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
protein binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
zinc ion binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
lipid binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
linoleic acid binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription activator activity	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
transcription coactivator binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
nuclear steroid receptor activity	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
nuclear receptor activity	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
protein binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
zinc ion binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
lipid binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
phosphatase binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
protein domain specific binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
mitogen-activated protein kinase kinase kinase binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
ubiquitin conjugating enzyme binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
sequence-specific DNA binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
protein-containing complex binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
NFAT protein binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
MDM2/MDM4 family protein binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Process	via Protein(s)	Taxonomy
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cytosol	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
intracellular membrane-bounded organelle	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
receptor complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor gamma	Mus musculus (house mouse)
nucleus	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
chromatin	Peroxisome proliferator-activated receptor delta	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
chromatin	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor alpha	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay ID	Title	Year	Journal	Article
AID156776	Binding affinity to bind to human Peroxisome proliferator activated receptor delta using scintillation proximity assay	2001	Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
AID157123	in vitro agonist activity against peroxisome proliferator activated receptor-gamma (PPAR-gamma), using alkaline phosphatase activity transactivator assay	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID91246	Agonist activity for Human PPAR gamma receptor in transcriptional activation assay	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID276983	Displacement of tritium labeled ligand from human PPARalpha by SPA assay	2006	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24	Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID91237	Agonist activity for Human PPAR alpha receptor in transcriptional activation assay	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID1507884	Transactivation of human Gal4-fused PPARalpha LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay relative to WY14643	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID188221	Compound was tested in vivo for Antihyperglycemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of plasma glucose	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID156456	Compound was tested functionally in vitro for inducing 50% of the maximum alkaline phosphatase activity (Transactivation) against murine Peroxisome proliferator activated receptor alpha using transfection assay in CV-1 cells; IA = Inactive at 10e-4 M	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID643836	Partial agonist activity at human PPARgamma LBD assessed as activation of CBP1-453 by HTRF assay relative to L-796449	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID156931	Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.	2001	Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
AID643841	Partial agonist activity at human PPARgamma LBD assessed as activation of PBP by HTRF assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID156442	In vitro transactivation of Peroxisome proliferator activated receptor alpha.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID157281	Compound was tested functionally in vitro for inducing 50% of the maximum alkaline phosphatase activity (Transactivation) against murine Peroxisome proliferator activated receptor gamma using transfection assay in CV-1 cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID643839	Partial agonist activity at human PPARgamma LBD assessed as activation of Src-1 by HTRF assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID157119	-log concentration required to induce 50% maximum lipogenic activity against Peroxisome proliferator activated receptor gamma	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID1507889	Modulation of SGK1 mRNA expression in HCCD cells at 20 uM after 24 hrs by RT-PCR method relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID21507	Solubility in simulated gastric fluid.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID276986	Activity at human PPARalpha expressed in CV1 cells using GAL4 chimeric system relative to control	2006	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24	Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID1507891	Anti-diabetic activity in ob/ob mouse assessed as change in serum triglyceride levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID156787	Compound was tested functionally in vitro for inducing 50% of the maximum alkaline phosphatase activity (Transactivation) against murine Peroxisome proliferator activated receptor delta using transfection assay in CV-1 cells; IA = Inactive at 10e-4 M	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID188208	Compound was tested for Antihyperlipidemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of NEFAs	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID156782	Compound was tested functionally in vitro for inducing 50% of the maximum alkaline phosphatase activity (Transactivation) against human Peroxisome proliferator activated receptor delta using transfection assay in CV-1 cells; IA = Inactive at 10e-4 M	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID141906	Agonist activity for murine PPAR alpha receptor in transcriptional activation assay;IA means inactive at 10 uM	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID276984	Displacement of tritium labeled ligand from human PPARgamma by SPA assay	2006	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24	Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID156783	The compound was tested in vitro for inhibiting the 50% binding of Peroxisome proliferator activated receptor delta	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID156130	Maximal reporter activity against human Peroxisome proliferator activated receptor alpha Gal4 chimeric in transiently transfected CV-1 cells by functional assay.	2001	Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
AID643840	Partial agonist activity at human PPARgamma LBD assessed as activation of Src-1 by HTRF assay relative to L-796449	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID1507893	Anti-diabetic activity in ob/ob mouse assessed as change in serum glucose levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID157120	Ability to promote differentiation of C3H10T1/2 stem cells to adipocytes using lipogenesis assay mediated through activation of Peroxisome proliferator activated receptor gamma	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID141912	Agonist activity for murine PPAR delta receptor in transcriptional activation assay;IA means inactive at 10 uM	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID306522	Intrinsic activity at PPARgamma receptor expressed in HEK293 cells at 1 uM by GAL4 transactivation assay relative to rosiglitazone	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID157124	Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID643835	Partial agonist activity at human PPARgamma LBD assessed as activation of CBP1-453 by HTRF assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID141913	Agonist activity for murine PPAR gamma receptor in transcriptional activation assay	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID306524	Displacement of fluorescein labeled ligand from PPARalpha receptor by fluorescence polarization assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID156448	The compound was tested in vitro for inhibiting the 50% binding of Peroxisome proliferator activated receptor alpha	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID599141	Agonist activity at PPARgamma	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	QSAR analysis of PPAR-gamma agonists as anti-diabetic agents.
AID117699	Compound was tested for Antihyperlipidemic activity, activity is expressed as percent reduction of Triglycerides	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID156444	Tested in vitro for inhibiting the 50% binding of Peroxisome proliferator activated receptor alpha	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID91245	Agonist activity for Human PPAR delta receptor in transcriptional activation assay;IA means inactive at 10 uM	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID306520	Displacement of fluorescein labeled ligand from PPARgamma receptor by fluorescence polarization assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID643838	Partial agonist activity at human PPARgamma LBD assessed as activation of PGC1 by HTRF assay relative to L-796449	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID21497	Solubility in pH 7.4 Phosphate buffer	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID117700	Compound was tested for Antihyperlipidemic activity, activity is expressed as percent reduction of body weight	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1507885	Transactivation of human Gal4-fused PPARalpha LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID157275	In vitro binding to peroxisome proliferator activated receptor gamma (PPAR gamma) using [3H]-BRL 49653 as radioligand in scintillation proximity assay (SPA)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID156288	Binding affinity to human Peroxisome proliferator activated receptor alpha using scintillation proximity assay	2001	Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
AID484773	Transactivation of PPARgamma assessed as induction of alkaline phosphatase activity	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).
AID643842	Partial agonist activity at human PPARgamma LBD assessed as activation of PBP by HTRF assay relative to L-796449	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID306525	Agonist activity at PPARalpha receptor expressed in HEK293 cells by GAL4 transactivation assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID306526	Intrinsic activity at PPARalpha receptor expressed in HEK293 cells at 1 uM by GAL4 transactivation assay relative to GW-2331	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID21981	The solubility determined by equilibrating an excess of solid material in 500 microL of simulated gastric fluid	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID1507895	Anti-diabetic activity in ob/ob mouse assessed as change in serum insulin levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID157271	Binding affinity against peroxisome proliferator activated receptor gamma (PPAR-gamma)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID276987	Activity at human PPARgamma expressed in CV1 cells by cotransfection assay relative to control	2006	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24	Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID157126	Tested functionally in vitro for inducing 50% of the maximum alkaline phosphate activity (Transactivation) against Peroxisome proliferator activated receptor gamma	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID117698	Compound was tested for Antihyperlipidemic activity, activity is expressed as percent reduction of NEFAs	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID306523	Agonist activity at PPARgamma receptor expressed in 3T3L1 cells assessed as differentiation of preadipocytes by GAL4 transactivation assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID643837	Partial agonist activity at human PPARgamma LBD assessed as activation of PGC1 by HTRF assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
AID188220	Compound was tested in vivo for Antihyperglycemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of HbA1C.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID157099	Binding affinity to human Peroxisome proliferator activated receptor gamma using scintillation proximity assay	2001	Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
AID21980	The solubility determined by equilibrating an excess of solid material in 500 microL of pH 7.4 phosphate buffer	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID157270	Inhibition by 50% of in vitro binding to Peroxisome proliferator activated receptor gamma	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID1507897	Toxicity in ob/ob mouse assessed as change in body weight at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID188209	Compound was tested for Antihyperlipidemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of Triglycerides	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID306521	Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
AID157121	Ability to promote differentiation of C3H10T1/2 stem cells to adipocytes using lipogenesis assay mediated through activation of Peroxisome proliferator activated receptor gamma	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
AID1507887	Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID156440	Compound was tested functionally in vitro for inducing 50% of the maximum alkaline phosphatase activity (Transactivation) against human Peroxisome proliferator activated receptor alpha using transfection assay in CV-1 cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1507888	Activation of recombinant human SIRT1 at 10 uM using C-terminal AMC labeled Arg-His-Lys-Lys (Ac) as substrate after 30 mins by FLUOR DE LYS fluorescent assay relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID117707	Compound was tested in vivo for Antihyperglycemic activity in mice, activity is expressed as percent reduction of plasma glucose.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1507886	Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay relative to rosiglitazone	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID1346733	Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The PPARs: from orphan receptors to drug discovery.
AID1346800	Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)	2004	European journal of biochemistry, Jan, Volume: 271, Issue:2	Binding analyses between Human PPARgamma-LBD and ligands.
AID1346733	Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)	2005	Pharmacology, Jan, Volume: 73, Issue:1	Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
AID1346800	Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1811	Experimentally measured binding affinity data derived from PDB	2000	Molecular cell, Mar, Volume: 5, Issue:3	Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2000	Molecular cell, Mar, Volume: 5, Issue:3	Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (8.82)	18.2507
2000's	24 (70.59)	29.6817
2010's	7 (20.59)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (8.57%)	5.53%
Reviews	1 (2.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (88.57%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.05	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.01	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.01	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
gw 2433 GW 2433: binds peroxisome proliferator-activated receptor alpha (PPARalpha); structure in first source	3.1	1	0
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	1.99	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	3.5	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	3.1	1	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.02	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	4.62	8	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	4.2	5	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
pirinixic acid pirinixic acid: structure	3.55	2	0	aryl sulfide; organochlorine compound; pyrimidines
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	2.02	1	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
aldosterone [no description available]	2.02	1	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	6.73	21	3	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	2.02	1	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.02	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.02	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.02	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	3.51	1	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	6.73	21	3	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.42	2	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.02	1	0	thiazolidine
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	2.02	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
bezafibrate [no description available]	3.1	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.02	1	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	2.03	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
rosiglitazone [no description available]	4.92	11	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)- 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-: an ET(A) and ET(B) endothelin receptor antagonist; structure in first source	2.02	1	0
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.02	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
mk 767 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source	3.1	1	0
jtt 501 JTT 501: an insulin sensitizer; structure in first source	3.1	1	0
1,2,3,4-tetrahydroisoquinoline carboxylic acid 1,2,3,4-tetrahydroisoquinoline carboxylic acid: RN given refers to cpd with locants as specified	2.04	1	0
muraglitazar muraglitazar: has glucose- and lipid-lowering activities; structure in first source; molecule composed of benzyloxazole-phenoxy-oxybenzylglycine-phenoxyl having structural analogy to PHENOXYBENZAMINE	2.48	2	0	1,3-oxazoles
tesaglitazar tesaglitazar: structure in first source	2.02	1	0
gw 409544 GW 409544: a PPARalpha agonist; structure in first source	2.02	1	0	monocarboxylic acid
drf 2725 ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma	2.02	1	0
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.02	1	0	prostaglandins D	human metabolite; mouse metabolite
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.02	1	0	benzamides
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.02	1	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2.02	1	0	alkaline earth metal atom; elemental barium
ici 118551 ICI 118551: RN given refers to (R,R)-(+-)-isomer; structure in first source; ICI 111581 is hydrochloride of ICI 118551. ICI 118551 : An indane substituted at position 7 by a methyl group and at position 4 by a 3-(isopropylamino)-2-hydroxybutoxy group (the 2R,3S-diastereomer).	2.02	1	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
gw 1929 GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first source	4.03	4	0	benzophenones
l-165041 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.	3.1	1	0	aromatic ketone
zd 7155 [no description available]	2.02	1	0
gw 9578 GW 9578: a peroxisome proliferator-activated receptor alpha agonist; structure in first source	3.1	1	0
gw 7845 GW 7845: ligand of the peroxisome proliferator-activated receptor-gamma; structure in first source	4.2	5	0
balaglitazone balaglitazone: structure in first source	3.51	1	1
l 796449 L 796449: a peroxisomal proliferator-activated receptor-gamma agonist; structure in first source	3.1	1	0
bm 131246 [no description available]	1.99	1	0
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.05	1	0
15-deoxyprostaglandin j2 15-deoxyprostaglandin J2: 15d-PGJ2 abbreviation is also used for 15-deoxy-delta(12,14)PGJ2	2.02	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Alloxan Diabetes [description not available]	0	2.92	4	0
Hyperlipemia [description not available]	0	2.92	1	0
Blood Pressure, High [description not available]	0	2.92	1	0
Innate Inflammatory Response [description not available]	0	2.92	1	0
Benign Neoplasms [description not available]	0	2.92	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	0	3.33	2	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	0	2.92	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	2.92	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.92	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.92	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	3.33	2	0
Diabetes Mellitus, Adult-Onset [description not available]	0	4.5	5	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	4.5	5	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.15	1	0
Left Ventricular Hypertrophy [description not available]	0	2.15	1	0
Cardiac Remodeling, Ventricular [description not available]	0	2.15	1	0
Cardiac Toxicity [description not available]	0	2.15	1	0
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	0	2.15	1	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	2.15	1	0
Cirrhosis, Liver [description not available]	0	4.43	2	2
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	1	6.43	2	2
Chronic Hepatitis C [description not available]	0	8.44	1	1
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	0	3.44	1	1
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	0	2.02	1	0
Insulin Sensitivity [description not available]	0	2.94	4	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	0	2.94	4	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.02	1	0
Anasarca [description not available]	0	3.42	1	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	8.42	1	1

farglitazar

Description

Cross-References

Synonyms (59)

Research Excerpts

Dosage Studied

Protein Targets (46)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (266)

Molecular Functions (68)

Ceullar Components (29)

Bioassays (78)

Research

Studies (34)

Market Indicators

Research Demand Index: 18.72

Study Types

farglitazar

Description

Cross-References

Synonyms (59)

Research Excerpts

Dosage Studied

Protein Targets (46)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (266)

Molecular Functions (68)

Ceullar Components (29)

Bioassays (78)

Research

Studies (34)

Market Indicators

Research Demand Index: 18.72

Study Types

Related Drugs (51)

Related Conditions (29)